

Comments

Please cancel claims 18-24.

The Examiner has restricted the Claims of the application to one of the following:

Group I, claim(s) 1-17, drawn to methods for the detection of a target nucleic acid,  
Group II, claim(s) 18-19 and 23, drawn to an oligonucleotide and a kit thereof, and  
Group III, claim(s) 20 and 24, drawn to a pair of primers and a kit thereof.

Without acquiescing to the restriction, Applicants elect Group I, claims 1-17.

Further, the Examiner has required an election of species of specific SEQ ID Nos.

Without Acquiescing to the election of species, Applicants elect SEQ ID Nos: 11, 15, and 17.

Conclusion


Applicants respectfully submit that this response is complete and responsive, and that the claims are in a condition for early consideration on the merits. In the event that a telephonic interview would be helpful, please contact the undersigned representative.

Please grant any additional extensions of time that may be required to enter this amendment and charge any additional fees or credit any overpayments to Deposit Account No. 50-0812.

Please direct all future correspondences to: Customer No. 22398.

Respectfully submitted,

Date: November 17, 2008

By:   
Robert W. Mann  
Reg. No. 48,555

Correspondence Address  
4300 Roche Molecular Systems, Inc.  
Hacienda Drive  
Pleasanton CA 94588  
Tel 925-730-8560  
Fax 925-225-1128